Drug Pipeline
30 drugs associated with Age-related macular degeneration
| Drug | Phase | Sponsor | |
|---|---|---|---|
0.5 mg Conbercept Intravitreal Injection Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor; Vascular endothelial growth factor C inhibitor | Phase 3 | Chengdu Kanghong Biotech Co., Ltd. | ↗ |
1.0 mg Conbercept Intravitreal Injection Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor; Vascular endothelial growth factor C inhibitor | Phase 3 | Chengdu Kanghong Biotech Co., Ltd. | ↗ |
2.0 mg Aflibercept Intravitreal Injection Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | Phase 3 | Chengdu Kanghong Biotech Co., Ltd. | ↗ |
ACU-4429 Retinoid isomerohydrolase inhibitor | Phase 3 | Kubota Vision Inc. | ↗ |
Aflibercept (2.0 mg) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | Phase 3 | EyePoint Pharmaceuticals, Inc. | ↗ |
EYP-1901 | Phase 3 | EyePoint Pharmaceuticals, Inc. | ↗ |
Lucentis or Avastin | Phase 3 | Clearside Biomedical, Inc. | ↗ |
Tinlarebant | Phase 3 | Belite Bio, Inc | ↗ |
Aflibercept (Eylea, BAY86-5321) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | unknown | Bayer | ↗ |
Lucentis (Ranibizumab) Vascular endothelial growth factor A inhibitor | unknown | University of Luebeck | ↗ |